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5-HT1B receptor radioligand [
11C]AZ10419369: a
comparative PET study in mouse, rat, and
guinea pig
Miklós Tóth1*, Jenny Häggkvist1, Andrea Varrone1, Sjoerd J Finnema1, Janine Doorduin1,2, Masaki Tokunaga3,
Makoto Higuchi3, Balázs Gulyás1,4 and Christer Halldin1,4Abstract
Background: We have explored the possibility that the serotonin 1B receptor radioligand [11C]AZ10419369 is a
substrate for adenosine triphosphate (ATP)-binding cassette (ABC) transporters, such as P-glycoprotein (P-gp), Mrp4,
and Bcrp, in rodents and whether there is a species difference regarding its blood-brain barrier (BBB) penetration.
Methods: In a series of preclinical positron emission tomography measurements, we have administered [11C]
AZ10419369 to mice, rats, and guinea pigs under baseline conditions and, on separate experimental days, after
administration of the ABC transporter inhibitor, cyclosporin A (CsA).
Results: During baseline conditions, the brain uptake was low in mice and rats, but not in guinea pigs. After CsA
pretreatment, the peak whole brain uptake values of [11C]AZ10419369 increased by 207% in mice, 94% in rats, and
157% in guinea pigs. Binding potentials (BPND) could not be estimated during baseline conditions in mice and rats.
After CsA pretreatment, the highest BPND values were obtained in the striatum and thalamus (BPND ≈ 0.4) in mice,
while in rats, the highest binding areas were the striatum, thalamus, hypothalamus, and periaqueductal gray
(BPND ≈ 0.5). In guinea pigs, we did not find any significant changes in BPND between baseline and CsA
pretreatment, except in the striatum.
Conclusions: The results indicate that BBB penetration of [11C]AZ10419369 was hindered by ABC transporter
activity in mouse, rat, and guinea pig. This study highlights the importance of ABC transporters in the design of
preclinical positron emission tomography (PET) studies.
Keywords: Positron emission tomography (PET); [11C]AZ10419369; Serotonin 1B (5-HT1B) receptor; Cyclosporin A
(CsA); Blood-brain barrier (BBB); ATP-binding cassette transporters (ABC transporters); Mouse; Rat; Guinea pig;
Species differenceBackground
In recent years, there has been a greater emphasis placed
on the use of small animal disease models during the early
phases of novel drug and diagnostic biomarker develop-
ment in molecular imaging with positron emission tomog-
raphy (PET). However, an increasing body of evidence
indicates that small animal models should be used with* Correspondence: Miklos.Toth@ki.se
1Centre for Psychiatry Research, Department of Clinical Neuroscience,
Karolinska Institutet, 171 76 Stockholm, Sweden
Full list of author information is available at the end of the article
© 2014 Tóth et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pcare [1]. The metabolic, pharmacokinetic, and toxico-
logical data obtained in small animals should be extrapo-
lated to other species or to humans rather carefully.
Species differences may result in significant differences be-
tween the efficacy and, consequently, the safety of the
same drug in the various species. These differences may
stem from various factors, including species differences in
drug metabolism, resulting from the genetic variations
in drug-metabolizing enzymes, which in turn may alter
pharmacokinetics, drug clearance, drug efficacy, and safety
[2]. Another possible factor resulting in species differencesOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cules (i) in the periphery in organs such as the liver, kid-
ney, and gastrointestinal tract or (ii) in the central nervous
system across the blood-brain barrier (BBB). Differences
in BBB penetration can have a serious impact on the use-
fulness and predictive value of small animal models in the
drug development process [3].
The transport of molecules across the BBB is partly pas-
sive (diffusion, based on concentration gradient differences)
and is partly active (based on various transporter molecules
and mechanisms) [4]. The most important transporters be-
long to the adenosine triphosphate (ATP)-binding cassette
(ABC) superfamily. In the brain, their role is distinctive in
the transport across the BBB. In the human genome, 48
genes encode the ABC transporters, which, based on se-
quence homologies, are divided into seven subfamilies (des-
ignated ABCA-ABCG) [5,6]. Several transporters from the
ABC family are expressed in the capillaries of the rat brain.
ABCB1, ABCC4, and ABCG2 are also present, but out
of these, the ABCB1 subfamily encoding P-glycoproteins
(P-gp; also called multidrug resistance 1 (Mdr1a)) is the
most abundant. In rats, the expression of P-gp is approxi-
mately 4 times higher than that of Bcrp (ABCG2) and 12
times higher than that of Mrp4 (ABCC4) [7]. In humans,
however, it has been found that Bcrp has a higher expres-
sion level than P-gp [8].
P-gp is a 170-kDa lipoprotein and is a well-characterized
member of the ABC family. P-gp is widely expressed in
plasma cell membranes across all vertebrate species and is
upregulated in multidrug-resistant tumors [5,6]. In the
BBB, P-gp contributes to the control of the pharmaco-
kinetics of various compounds. It has been suggested that
P-gp-mediated drug efflux may play a decisive role in the
development and maintenance of various disorders, in-
cluding, among others, multidrug-resistant cancer and
drug-resistant epilepsies [9]. Differences in P-gp expres-
sion across different species have been reported for rat,
guinea pig, and monkey [10].
[11C]AZ10419369 is an 11C-radiolabelled analogue of a
serotonin 1B (5-HT1B) candidate drug, AZ10419369, and a
novel radioligand developed for the selective visualization
of the 5-HT1B receptors with PET [11,12]. Whereas the
radioligand [11C]AZ10419369 has been demonstrated to be
a good marker of drug-induced occupancy at central 5-
HT1B receptors in the primate brain [13,14], initial mea-
surements showed poor brain penetration in rats (unpub-
lished data). In the present study, we set out to explore the
possibility that [11C]AZ10419369 is a substrate for ABC
transporters in rodents and, consequently, if there is a spe-
cies difference regarding its BBB penetration.
The main objective of the present investigation was
to explore the differences in BBB transport of [11C]
AZ10419369, with special regard to the ABC transporter
activities, in three rodent species widely used in preclinicaldrug development studies: mouse, rat, and guinea pig.
PET measurements were performed after i.v. injection of
[11C]AZ10419369 under baseline conditions as well as




Eight male C57BL/6J mice, seven male Wistar rats, and
seven male Dunkin-Hartley guinea pigs were used in the
study. The animals were housed in groups in individually
ventilated cages in a thermoregulated (approximately 22°C),
humidity-controlled facility under a 12-h/12-h light/dark
cycle with access to food and water ad libitum.
All animal experiments were conducted according to the
guidelines of the Swedish National Board of Laboratory
under a protocol approved by the Ethics Review Board of
Northern Stockholm, Sweden (N210/10, N557/11).
Radiochemistry and drugs
[11C]AZ10419369 was prepared at Karolinska Institutet by
N-methylation of the desmethyl precursor (8-(1-piperazi-
nyl)-5-methylchrom-2-en-4-one-2-(4-morpholi-nophenyl)
carboxamide, AstraZeneca R&D, Wilmington, DE, USA),
using [11C]methyl triflate, as described in detail earlier
[11]. CsA (50 mg/mL, formulated in 96% ethanol) was
purchased from Novartis Sverige AB (Täby, Sweden).
In vivo imaging with PET
On the experimental day, the animals were anesthetized
by inhalation of isoflurane (4% to 5% isoflurane in 100%
oxygen). After induction of anesthesia, the isoflurane con-
centration was lowered to 1.5% to 2% (50:50 air/oxygen)
and a cannula was inserted in the tail vein in mouse and
rat and in the tarsal vein in the case of guinea pig. The ani-
mals were positioned in the PET camera in transaxial pos-
ition with their heads in the center of the field of view.
[11C]AZ10419369 was intravenously administered simul-
taneously with the start of the PET acquisition and was
followed by a 0.1-mL saline flush.
Eight male C57BL/6J mice (28.3 ± 0.8 g) were intraven-
ously injected with [11C]AZ10419369 twice, 1 week apart.
The average injected radioactivity was 10.8 ± 0.9 MBq
(n = 16), and the average injected mass was 0.025 ± 0.024
μg (n = 16). Seven male Wistar rats (322 ± 46 g) were
intravenously injected with [11C]AZ10419369 twice, 1
week apart. The mean injected radioactivity was 21.5 ± 2.7
MBq (n = 14), and the average injected mass is not avail-
able. Seven male guinea pigs (514.4 ± 146.9 g) were intra-
venously injected with [11C]AZ10419369 twice, 1 week
apart. The average injected radioactivity was 16.8 ± 3.2
MBq (n = 14), and the average injected mass was 0.020 ±
0.022 μg (n = 14). Upon completion of the first imaging
session, the animal returned to its cage. Before the start of
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treated with 50 mg/kg CsA, administered intravenously
15 min before the injection of the radioligand through the
same cannula as used for radioligand injection.
Imaging system and reconstruction
The PET measurements were acquired using the Mediso
nanoScan® PET-MRI and the nanoScan® PET-CT small
animal imaging systems (Mediso Ltd., Budapest, Hungary)
[15,16]. Two animals were examined at the same time in
the identical PET modules of the two PET systems. The
acquired list mode data was reconstructed into 25 time
frames (63-min scan = 4 × 10 s, 4 × 20 s, 4 × 60 s, 7 × 180 s,
6 × 360 s) in the case of mice and rats and 35 time frames
(93-min scan = 4 × 10 s, 4 × 20 s, 4 × 60 s, 7 × 180 s, 11 ×
360 s) in the case of guinea pigs.
The image reconstruction was made with a fully three-
dimensional maximum-likelihood expectation maximization
(MLEM) algorithm with 20 iterations, without scatter and
attenuation correction.
Data analysis
The reconstructed dynamic mouse and rat PET images
were co-registered to the inbuilt mouse and rat MRI tem-
plates available in PMOD, which also incorporates volume
of interest (VOI) sets for mice and rats (version 3.3, PMOD
Technologies Ltd., Zurich, Switzerland). Co-registration
was done manually with the use of mean PET images. For
the guinea pig scans, a template MRI with an in-house de-
veloped VOI set was used to co-register with the PET scans.
With the help of these VOI sets, decay-corrected time ac-
tivity curves (TAC) were generated. Whole brain and re-
gional brain uptake values were expressed as percent
standard uptake value (%SUV), which was calculated by
normalizing regional radioactivity for injected radioactivity
and body weight. Uptake values were then calculated as a
summation of uptake from 10 min to the end of the PET
acquisition (total 53 min in the case of rats and mice and
113 min in the case of guinea pigs).
As the %SUV is considered a semi-quantitative value,
quantitative image analysis was additionally performed
using PMOD. The non-displaceable binding potential
(BPND) was estimated using the simplified reference tissue
model (SRTM) [17] using the cerebellum as reference re-
gion (mice and rats) or cerebellar gray matter (guinea
pigs). This is a validated quantitative analysis method for
[11C]AZ10419369 binding in humans [13] and has been
used in non-human primates [14]. Statistical analyses were
performed with Student's two-tailed, paired t-test.
Results
At baseline conditions, the guinea pigs showed distin-
guishable brain uptake compared to the surrounding tis-
sue, whereas low brain uptake was observed in the ratsand mice (Figure 1). There was a statistically significant
increase in %SUV after CsA pretreatment compared to
baseline images in all regions, for all animal species
(Table 1). Peak whole brain uptake values increased by
207% in mice, 94% in rats, and 157% in guinea pigs after
CsA pretreatment.
A fast clearance of [11C]AZ10419369 was demon-
strated in mice and rats, while there was a slow washout
in guinea pigs in both the baseline and after pretreat-
ment with CsA (Figure 1). During baseline conditions,
peak brain uptake was at 0.4 min in mice and rats and
at 84 min in guinea pigs. After CsA administration, the
peak brain uptake in mice was at 1.5 min and at 1.2 min
in rats. However, in guinea pigs, [11C]AZ10419369 did
not reach equilibrium during the 2-h-long PET acquisi-
tion in all regions examined besides the cerebellum.
As the initial counts in brain were very low in mice
and rats at baseline condition, the binding potential of
[11C]AZ10419369 could only be estimated reliably in
guinea pigs. After administration of CsA, the brain up-
take had increased sufficiently, and therefore, we quanti-
fied BPND in all three species (Table 1).
After CsA pretreatment, the highest BPND values were
found in the striatum and thalamus in mice (BPND ≈ 0.4).
In rats, the highest BPND values were observed in the stri-
atum, thalamus, hypothalamus, and periaqueductal gray
(BPND ≈ 0.5). In guinea pigs, the cerebellar gray matter
was selected as the reference region instead of the whole
cerebellum since there was a relative high concentration
of [11C]AZ10419369 in the white matter. We found no
changes in BPND between baseline and CsA pretreat-
ment in guinea pigs except in the striatum where a
significant decrease in binding (BPND 3.1 to 2.4) was
observed. This is probably due to the fact that none of
the regions could reach equilibrium during our experi-
ments making the SRTM calculations unreliable despite
the 2-h scan.
Discussion
An increasing number of recent observations [10,18,19]
indicate that the brain concentration of a drug can differ
significantly among various species. These species differ-
ences can be traced back to various factors, including
differences in plasma binding, metabolic enzyme activ-
ities, or BBB transport. As several biologically effective
compounds may be substrates of efflux transporters, like
P-gp, one of the most important mechanisms behind
species differences in drug disposition in the brain can
be traced back to this phenomenon, i.e., that a CNS drug
is a substrate of P-gp in a given species.
Although CsA had been mostly used as a P-gp inhibi-
tor in relation to the brain, in the periphery, it has been
shown to inhibit transporters from the solute carrier
membrane transport protein group as well [20,21]. Since
Figure 1 PET images and TAC curves of [11C]AZ10419369 uptake in mouse, rat, and guinea pig. Representative uptake images (left) and
time activity curves of striatal and cerebellar uptake (right) of [11C]AZ10419369 in mouse (top), rat (middle), and guinea pig (bottom) in baseline
and pretreatment conditions. The images are a summation from 10 min until the end of the scan (total 53 min in the case of rat and mice and
113 min in the case of guinea pig), while TAC curves are presented as mean values and SD as error bars in mice (n = 8), in rats (n = 7), and in
guinea pigs (n = 7).
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distribution, brain penetration, and metabolism, this fact
has to be taken into consideration while assessing the re-
sults. Metabolic differences under different pretreatmentconditions could be a critical factor in brain uptake levels,
since non-identical free fraction of [11C]AZ10419369 in
the blood leads to different availability of radioligand for
transport across the BBB. Arterial blood sampling is
Table 1 Comparison of regional uptake and binding potential in the different brain regions
Mouse Rat Guinea pig
Baseline CsA P value Baseline CsA P value Baseline CsA P value
%SUV
Whole brain 33.4 ± 2.4 98.6 ± 10.8 0.0000 37.4 ± 4.1 119.0 ± 29.3 0.0002 259.6 ± 34.6 643.1 ± 192.4 0.0020
Cortex 30.9 ± 2.6 95.1 ± 10.6 0.0000 38.7 ± 4.2 113.0 ± 26.7 0.0002 213.3 ± 27.3 566.9 ± 198.1 0.0027
Striatum 28.6 ± 2.4 110.4 ± 12.1 0.0000 37.0 ± 5.8 146.9 ± 43.5 0.0003 394.4 ± 58.7 768.3 ± 299.9 0.0205
Thalamus 29.3 ± 2.2 114.4 ± 14.1 0.0000 36.2 ± 5.3 145.5 ± 41.8 0.0003 301.5 ± 44.9 792.1 ± 216.4 0.0015
Hypothalamus 40.3 ± 2.3 107.8 ± 10.3 0.0000 41.2 ± 5.9 143.6 ± 39.7 0.0003 354.9 ± 60.9 794.3 ± 204.1 0.0019
Hippocampus 28.0 ± 2.2 102.6 ± 11.0 0.0000 35.6 ± 4.6 137.3 ± 40.1 0.0003 228.3 ± 31.7 605.7 ± 171.1 0.0011
Central canal-PAG 27.1 ± 1.8 106.3 ± 13.4 0.0000 37.4 ± 5.3 147.4 ± 38.7 0.0002 446.2 ± 71.8 986.5 ± 248.0 0.0027
Colliculus inferior 28.0 ± 2.6 107.1 ± 12.9 0.0000 36.7 ± 4.1 138.7 ± 38.0 0.0003 192.7 ± 30.3 900.5 ± 264.7 0.0005
Colliculus superior 28.1 ± 2.9 94.1 ± 10.2 0.0000 34.4 ± 4.3 127.9 ± 32.2 0.0002 428.4 ± 69.7 1 072.5 ± 291.8 0.0018
Midbrain 30.8 ± 2.4 111.5 ± 12.5 0.0000 37.4 ± 4.3 143.6 ± 36.7 0.0002 409.5 ± 67.6 970.1 ± 245.5 0.0018
Cerebellum 33.7 ± 3.1 81.1 ± 8.6 0.0000 34.0 ± 3.3 96.4 ± 18.3 0.0001 162.7 ± 24.8 467.5 ± 135.8 0.0006
Cerebellum GM - - - - - - 120.8 ± 17.4 372.6 ± 122.1 0.0009
BPND
Whole brain - 0.19 ± 0.04 n/a - 0.21 ± 0.10 n/a 1.56 ± 0.39 1.57 ± 0.44 n.s.
Cortex - 0.12 ± 0.04 n/a - 0.15 ± 0.10 n/a 1.00 ± 0.23 1.23 ± 0.30 n.s.
Striatum - 0.39 ± 0.08 n/a - 0.48 ± 0.21 n/a 3.13 ± 0.90 2.36 ± 0.52 0.0224
Thalamus - 0.39 ± 0.16 n/a - 0.48 ± 0.18 n/a 2.05 ± 0.55 2.29 ± 0.72 n.s.
Hypothalamus - 0.30 ± 0.06 n/a - 0.45 ± 0.15 n/a 2.76 ± 0.74 2.81 ± 1.04 n.s.
Hippocampus - 0.25 ± 0.11 n/a - 0.39 ± 0.18 n/a 1.25 ± 0.29 1.38 ± 0.38 n.s.
Central canal-PAG - 0.15 ± 0.17 n/a - 0.50 ± 0.11 n/a 4.06 ± 1.36 5.00 ± 3.04 n.s.
Colliculus inferior - 0.17 ± 0.19 n/a - 0.42 ± 0.12 n/a 3.08 ± 0.86 4.00 ± 1.54 n.s.
Colliculus superior - 0.13 ± 0.06 n/a - 0.27 ± 0.14 n/a 3.50 ± 1.15 3.65 ± 1.11 n.s.
Midbrain - 0.26 ± 0.20 n/a - 0.46 ± 0.11 n/a 3.34 ± 1.01 3.40 ± 1.17 n.s.
Cerebellum - - - - - - 0.52 ± 0.16 0.49 ± 0.44 n.s.
Regional uptake and binding potential of [11C]AZ10419369 in the different brain regions in mice, rats, and guinea pigs during baseline and CsA pretreatment
conditions (each value represents mean ± SD). n/a, not applicable; n.s., not significant.
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the free fraction over time. This is a rather difficult task in
rodents, particularly in mice, in which the required blood
volume would exceed the total blood volume of the ani-
mal. The effects of blood loss from arterial blood sampling
could reduce the blood volume to such extent that it may
alter metabolism, influence Vt, or even cause severe health
issues which could lead to exsanguination and conse-
quently to the death of the animal.
While the effects of CsA on the periphery could have
been assessed with arterial blood measurement, we did
not perform this for the aforementioned reasons. These
effects can be avoided by using various transporter knock-
out animal models. In a complementary study using
Sprague-Dawley rats and Mdr1a knockout animals, we
have examined the difference in brain uptake and 5-HT1B
receptor availability with [11C]AZ10419369 microPET.
Increased uptake and [11C]AZ10419369 BPND were ob-
served in KO rats compared with WT in some brainregions, suggesting that the brain uptake of [11C]
AZ10419369 is influenced at least by Mdr1a function (see
Additional file 1). Earlier PET studies have indicated that
the brain uptake of various P-gp substrates may differ
markedly between rodent and primate species [10,22-24].
It has also been demonstrated that there can be species
difference in BBB transport between various rodent spe-
cies [10,25]. This fact can be substantiated by the compari-
son of amino acid content in P-gp in rats, mice, and
guinea pigs: the amino acid homology between mouse and
rat is 93%, between mouse and guinea pig is 82%, and be-
tween rat and guinea pig is 80% [10].
The experiments with mice and rats showed that the
rather low brain uptake of [11C]AZ10419369 during
baseline condition could be increased significantly with
the use of CsA. The brain uptake increased significantly
in all species, and the binding potential became measur-
able after CsA pretreatment in mice and rats. In guinea
pigs, the uptake of [11C]AZ10419369 was increased
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but the BPND showed no changes compared to baseline
in all regions except for the striatum, where a significant
decrease was observed compared to baseline. It is pos-
sible that this difference between species could disappear
with longer scanning times. However, as the guinea pigs
had breathing difficulties under long-term anesthesia, in-
creased scan time was not applied for ethical reasons.
The difference in BPND observed in guinea pigs, com-
pared with mice and rats, is most likely due to the differ-
ences in homology of the 5-HT1B receptor in the guinea
pig versus that in the rat and mouse. A previous report
indicated that amino acid residue 335 in the 5-HT1B re-
ceptor is a major determinant of its reactivity with sev-
eral ligands [26]. It has also been shown that [3H]
AZ10419369 has high affinity (Kd = 0.4 nM) for both hu-
man and guinea pig 5-HT1B receptors, and AZ10419369
binds to human (Ki = 0.8 nM) and guinea pig 5-HT1B re-
ceptors (Ki = 0.01 nM) with higher affinity than it does
to rat 5-HT1B receptors (Ki = 2.3 nM) [12]. Furthermore,
our results show good agreement with the in vivo results
of Maier et al. (2009) on guinea pig brain distribution of
[3H]AZ10419369 [27]. Thus, the current study seems to
confirm the difference in Kd across species in vivo, with
lower binding affinity to the mouse and rat 5-HT1B re-
ceptor and with the highest affinity to the receptor in
the guinea pig.
The results from the present study further support the
importance of evaluating the outcome of small animal
model experiments with caution especially when it comes
to drug development studies. Since there can be species
differences in transporter function, as shown in the
present study, different promising radioligands targeted
for the brain may be discarded on incorrect conclusions.
Conclusions
This study showed that [11C]AZ10419369 is a substrate
for ABC transporters in mouse, rat, and guinea pig. Our
results suggest that the activity of ABC transporters,
such as P-gp, as well as possible species differences in
the receptor affinity of radioligands, are important fac-
tors to consider in the design of preclinical PET studies.
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